全球病毒載體製造市場與技術 -GII

来自 : www.giichinese.com.tw/report/b 发布时间：2021-03-26

Table 1: Characteristics of Potential Viral Vaccine VectorsTable 2: Advantages and Disadvantages of Major Viral VectorsTable 3: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 vs. 2022Table 4: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 and 2022Table 5: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022Table 6: Vaccine Designs and Strategies for Their Utility Against HIVTable 7: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022Table 8: Driver Impact Analysis for Global Viral Vector Vaccine Manufacturing MarketTable 9: List of Clinical Trials with Their Conditions and InterventionsTable 10: Distribution of Diseases Targeted by Prophylactic Gene-Based VaccinesTable 11: Properties of Various Viral Vectors and Their Application in Gene TherapyTable 12: Global Incidence of Chronic Diseases, 2005-2030Table 13: Global Prevalence of Colon Cancer, by Age Group, 2016Table 14: Global Incidence of HIV Disease, by Region, 2016Table 15: Various Types of Viral Vectors Used in Gene Therapy and Their AdvantagesTable 16: Characteristics of Key Viral VectorsTable 17: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 18: Global Adenoviral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 19: Global Retroviral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 20: Advantages and Disadvantages of Retroviral VectorsTable 21: List of Retroviral Vector Vaccines under Development as of March 2018Table 22: Components of HIV ProvirusTable 23: Clinical Trials Deploying Lentiviral Vectors for Modification of Hematopoietic Stem Cells by PhaseTable 24: Global Lentiviral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 25: Second- versus Third-Generation Lentiviral SystemsTable 26: Selected AAV Vectors with Their Tropisms and ReceptorsTable 27: Global Adeno-associated Vector Vaccine Manufacturing Market, by Region, Through 2022Table 28: Global Cytomegalovirus Vector Vaccine Manufacturing Market, by Region, Through 2022Table 29: Human Cytomegalovirus Vaccine Candidates in Different Stages of Preclinical and Clinical DevelopmentTable 30: Licensed Fowl Pox Viral-Vectored Veterinary VaccinesTable 31: Global Pox Virus Vector Vaccine Manufacturing Market, by Region, Through 2022Table 32: Benefits and Drawbacks of HSV Viral VectorsTable 33: Global Other Viral Vector Vaccines Manufacturing Market, by Region, Through 2022Table 34: HSV Proposed Vaccines and Their CharacteristicsTable 35: Global Viral Vector Vaccine Manufacturing Market, by Disease Segment, Through 2022Table 36: Licensed Viral and Bacterial Vaccines for Use in HumansTable 37: Global Viral Vector Vaccine Manufacturing Market, by Human Disease Application, Through 2022Table 38: Global Viral Vector Manufacturing Market in Human Disease, by Region, Through 2022Table 39: Pricing in Gavi Countries: Product-Specific CommitmentsTable 40: Estimated New Cases of HAVTable 41: Number of Death Certificates Listing HAV, HBC and HCV as a Cause of Death, 2015 and 2016Table 42: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015Table 43: Leading Sites of Estimated New Cancer Cases in U.S, 2017Table 44: Virus-Vectored Experimental Influenza VaccinesTable 45: Some of the Delivery Vectors Evaluated in Clinical Studies for HIV VaccinesTable 46: People Living with HIV, by Region, 2016Table 47: Tuberculosis Viral Vector Vaccine CandidatesTable 48: Ongoing Preclinical Development and Clinical Trials on Malaria VaccinesTable 49: Top 10 Priority Initiatives for Malaria Vaccine Development According to the Malaria Vaccine Technology RoadmapTable 50: Ongoing Clinical Trials of Vector Vaccines against EVD, As of 2017Table 51: EVD Cases and Death, by CountryTable 52: Zika Virus Vaccine Development and Ongoing Clinical TrialsTable 53: Licensed Viral-Vectored Veterinary VaccinesTable 54: Global Estimates of the Growth in Demand for Meat, 2010-2030Table 55: Global Viral Vector Vaccine Manufacturing Market, by Veterinary Disease Application, Through 2022Table 56: Global Viral Vector Vaccine Manufacturing Market for Veterinary Disease Application, by Region, Through 2022Table 57: Avian Influenza VaccinesTable 58: Global Estimates of Poultry ProductionTable 59: Marek\'s Disease VaccinesTable 60: Grants Supporting the Development of Novel Recombinant Adenovirus-Based Vaccine Candidates for Respiratory Diseases in ChickensTable 61: Global Viral Vector Vaccine Manufacturing Market, by Application, Through 2022Table 62: Comparison of the Viral Vectors Discussed Based on Specific Vector CharacteristicsTable 63: Global Multivalent Viral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 64: Global Incidence of HIV Disease, by Region, 2015 and 2016Table 65: Global Incidence of TB, by Region, 2016Table 66: Global Multipathogen Viral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 67: Overview of Multivalent/Polyvalent and Multipathogen/Multidisease Viral Vector Vaccine Candidates, by VectorTable 68: Global Viral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 69: North American Viral Vector Vaccine Manufacturing Market, by Country, Through 2022Table 70: North American Viral Vector Manufacturing Market, by Type, Through 2022Table 71: Cancer Research Funding in the U.S., 2015 and 2016Table 72: North American Viral Vector Manufacturing Market, by Application Type, Through 2022Table 73: U.S. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 74: North American Viral Vector Manufacturing Market, by Disease Segment, Through 2022Table 75: NIH Funding for CRISPR-Related Research, 2006-2016Table 76: North American Viral Vector Manufacturing Market, by Human Disease Application, Through 2022Table 77: New HIV Diagnoses in the U.S., by Age Group, 2016Table 78: Viral Vector Vaccines in Development in U.S.Table 79: Canadian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 80: North American Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022Table 81: Confirmed Influenza Cases in Mexico, 2012-2016Table 82: Mexican Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 83: European Viral Vector Vaccine Manufacturing Market, by Country, Through 2022Table 84: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018Table 85: Recent Impact of HPAI in Domestic Birds, by Region, February 2018Table 86: German Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 87: European Viral Vector Manufacturing Market, by Type, Through 2022Table 88: U.K. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 89: European Viral Vector Manufacturing Market, by Application Type, Through 2022Table 90: HIV/AIDS Statistics in the U.K., 2015Table 91: People Living with HIV (All Ages) in France, 2000-2016Table 92: French Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 93: Distribution of the Leading Causes of Death in Women in France, 2017Table 94: Distribution of the Leading Causes of Death in Men in France, 2017Table 95: European Viral Vector Manufacturing Market, by Disease Segment, Through 2022Table 96: European Viral Vector Manufacturing Market, by Human Disease Application, Through 2022Table 97: HPAI Outbreaks in Poultry and Wild Bird Cases in the E.U., October 2016 - July 2017Table 98: European Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022Table 99: Spanish Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 100: Number of People in Spain Infected with HIV, by Age, 2000-2016Table 101: Italian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 102: Italian Poultry Meat Production, 2016Table 103: Rest of Europe Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 104: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016Table 105: Asia-Pacific Viral Vector Vaccine Manufacturing Market, by Country, Through 2022Table 106: Asia-Pacific Viral Vector Manufacturing Market, by Type, Through 2022Table 107: Chinese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 108: Asia-Pacific Viral Vector Manufacturing Market, by Application Type, Through 2022Table 109: Ongoing Preclinical and Clinical Trials of HIV/AIDS Vaccine in ChinaTable 110: Asia-Pacific Viral Vector Manufacturing Market, by Disease Segment, Through 2022Table 111: Confirmed Cases of Human Infection with Avian Influenza in China, 2013 and 2016Table 112: Asia-Pacific Viral Vector Manufacturing Market, by Human Disease Application, Through 2022Table 113: Indian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 114: Prevalence of Tuberculosis Cases in India, 2016Table 115: Asia-Pacific Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022Table 116: Ongoing Clinical Trials Related to HIV Vaccines in IndiaTable 117: Japanese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 118: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016Table 119: Australian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 120: Various Viral Vaccine Vectors Used in AIDS Vaccine DevelopmentTable 121: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016Table 122: South Korean Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 123: HPAI Outbreaks in South Korea, 2003-2017Table 124: Vaccine Strains for Immunization of Chickens against H5N1 HPAIVSTable 125: Distribution of Causes of Death in South Korea, 2016Table 126: Rest of APAC Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 127: Leading Causes of Deaths in Singapore, 2014-2016Table 128: Mortality by Sex and Cause of Death, 2016Table 129: HIV/AIDS Statistics for Thailand, 2016Table 130: Ongoing Clinical Trials for Preventive HIV Vaccine Candidates in ThailandTable 131: Estimated Worldwide Rates of Skin Cancer per CapitaTable 132: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016Table 133: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017Table 134: ROW Viral Vector Vaccine Manufacturing Market, by Region, Through 2022Table 135: ROW Viral Vector Manufacturing Market, by Type, Through 2022Table 136: Latin American Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 137: Poultry Consumption across ROW Countries, 2017Table 138: ROW Viral Vector Manufacturing Market by Application Type Through 2022Table 139: Top 10 Causes of Deaths in Cuba and Percentage Change from 2005 to 2016Table 140: Middle East and African Viral Vector Vaccine Manufacturing Market, by Type, Through 2022Table 141: ROW Viral Vector Manufacturing Market, by Disease Segment, 2017-2022Table 142: Characteristics of the Priority Diseases Identified in the WHO R&D Blueprint, Revised, 2017Table 143: ROW Viral Vector Manufacturing Market, by Human Disease Application, Through 2022Table 144: ROW Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022Table 145: Viral Vector OverviewTable 146: Related Impurities to be Eliminated, by Downstream ProcessingTable 147: Viral Vector Manufacturing SuppliersTable 148: List of Some of the Viral Vector ProducersTable 149: List of Company ExpansionTable 150: List of CollaborationsTable 151: List of InvestmentsTable 152: List of AcquisitionsTable 153: U.S. Viral Vector Vaccine Manufacturing Patents, 2015-May 2018Table 154: European Viral Vector Vaccine Manufacturing Patents, 2015-May 2018Table 155: Japanese Viral Vector Vaccine Manufacturing Patents, 2015-May 2018Table 156: Advanced BioScience Laboratories Product PortfolioTable 157: Advanced BioScience Laboratories Recent Developments, 2015-April 2018Table 158: Advanced Biotherapeutics Consulting Product PortfolioTable 159: Applied Viromics Product PortfolioTable 160: Batavia Biosciences Product PortfolioTable 161: Batavia Bioscience Recent Developments, 2015-April 2018Table 162: Benitec Biopharma Product PortfolioTable 163: Biogen Product PortfolioTable 164: Biogen Recent Developments, 2015-April 2018Table 165: Biovian Product PortfolioTable 166: Boehringer Ingelheim Product PortfolioTable 167: Brammer Bio Product PortfolioTable 168: Brammer Bio Recent Developments, 2015-April 2018Table 169: Cell and Gene Therapy Catapult Product PortfolioTable 170: Cell and Gene Therapy Catapult Recent Developments, 2015 - April 2018Table 171: Ceva Product PortfolioTable 172: Cobra Biologics Product PortfolioTable 173: Cobra Biologics Recent Developments, 2015 - April 2018Table 174: Creative Biogene Product PortfolioTable 175: GE Healthcare Product PortfolioTable 176: GeneDetect Product PortfolioTable 177: GenVec Product PortfolioTable 178: ID Pharma Product PortfolioTable 179: Janssen Product PortfolioTable 180: Janssen Recent Developments, 2015 - April 2018Table 181: Lonza Group Product PortfolioTable 182: Lonza Group Recent Developments, 2015 - April 2018Table 183: Merck Millipore Product PortfolioTable 184: Merck Millipore Recent Developments, 2015 - April 2018Table 185: Miltenyi Biotec Product PortfolioTable 186: MolMed Product PortfolioTable 187: Paragon Bioservices Product PortfolioTable 188: Paragon Bioservices Recent Developments, 2015 - April 2018Table 189: Pfizer Product PortfolioTable 190: Pfizer Recent Developments, 2015 - April 2018Table 191: Sanofi Product PortfolioTable 192: Sementis Product PortfolioTable 193: Spark Therapeutics Product PortfolioTable 194: Spark Therapeutics Recent Developments, 2015 - April 2018Table 195: Synpromics Product PortfolioTable 196: Synpromics Recent Developments, 2015 - April 2018Table 197: Valneva Product PortfolioTable 198: Vector Biolabs Product PortfolioTable 199: Vigene Biosciences Product PortfolioTable 200: Vigene Biosciences Recent Developments, 2015 - April 2018Table 201: Virovek Product Portfolio